Product Name: Dapagliflozin CAS NO:461432-26-8
Chemical & Physical Properties:
Appearance :white powder
Boiling Point:609℃ at 760 mmHg
Dapagliflozin (ForxigaTM) is a new anti-diabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca. It was approved by the European Medicines Agency (EMA) on November 12, 2012. It is The first SGLT2 inhibitor approved to be marketed for the treatment of type 2 diabetes can be used as an important choice in the treatment of diabetes, and is suitable for use as an auxiliary diet and exercise to improve blood sugar control in adults with type 2 diabetes.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.